Fulcrum Therapeutics, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. Fulcrum is a clinical-stage biotechnology company developing small molecules for genetically defined rare diseases. It reported no product sales revenue; collaboration revenue was its only reported revenue.
Financial performance and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Collaboration revenue | $0.8m | $1.2m | $1.9m | $5.7m |
| Research and development expense | $18.2m | $15.4m | $52.8m | $58.2m |
| General and administrative expense | $10.0m | $9.7m | $31.8m | $31.6m |
| Operating loss | $27.4m | $24.4m | $82.7m | $84.6m |
| Net loss | $24.0m | $23.7m | $72.6m | $83.7m |
| Net loss per share, basic and diluted | $0.39 | $0.51 | $1.19 | $1.97 |
Amounts are losses unless otherwise indicated. Q3 operating expenses totaled $28.2m; the filing does not present a meaningful product gross margin because Fulcrum has no product sales. Other income was $3.4m in Q3 and $10.1m for the nine months, primarily reflecting investment returns.
At September 30, 2023, cash and cash equivalents were $30.1m and marketable securities were $227.0m, totaling $257.1m. Current assets were $262.5m and current liabilities $14.1m. Stockholders’ equity was $255.5m; accumulated deficit was $484.9m. The filing reports no credit facility or committed capital source and no borrowings; lease liabilities totaled $11.5m.
Net cash used in operating activities was $67.8m for the nine months, versus $77.4m in 2022. Investing activities used $55.0m, largely reflecting net purchases of marketable securities, compared with $48.8m provided in 2022. Financing provided $117.8m, mainly from the January 2023 common-stock offering. Cash, cash equivalents and restricted cash decreased $5.0m to $31.2m.
Material changes versus the prior comparable period
- Nine-month net loss narrowed by $11.2m, although Q3 net loss increased by $0.3m. Higher investment income substantially supported the nine-month improvement.
- Nine-month collaboration revenue fell $3.7m: the Acceleron collaboration had ended in October 2022, and MyoKardia revenue recognition was lower.
- Nine-month R&D expense declined $5.4m, including lower pociredir costs during its clinical hold and absence of the $5.0m GSK milestone recorded in 2022. Q3 R&D rose $2.9m, mainly as the losmapimod Phase 3 trial advanced.
- In January 2023, Fulcrum issued 9.6m shares at $13.00 per share, receiving net proceeds of $117.3m. Shares outstanding were 61.8m at September 30, versus 52.1m at December 31, 2022.
Outlook, developments and principal risks
- Management said September 30 cash, cash equivalents and marketable securities were expected to fund operating expenses and capital requirements into 2026. This estimate depends on assumptions and could prove shorter; the company expects continuing losses and may need further financing.
- Losmapimod: the Phase 3 REACH trial for FSHD completed enrollment of 260 patients in September 2023. Topline results were expected in Q4 2024.
- Pociredir: the FDA placed the SCD investigational new drug application on full clinical hold in February 2023, citing hematological malignancies in nonclinical toxicology studies; the hold was lifted in August. The Phase 1b trial was to resume at 12 mg once daily, followed by a planned 20 mg cohort, with revised eligibility criteria targeting patients with higher disease severity. Safety, enrollment and efficacy remain uncertain.
- Fulcrum said it was focusing resources on its two clinical-stage programs and winding down certain exploratory discovery activities. It also licensed CAMP4’s Diamond Blackfan Anemia program in July 2023 for an undisclosed upfront payment, with potential milestones and royalties.
- A securities class action alleges misleading statements or omissions concerning the pociredir clinical hold and seeks damages, among other relief. Fulcrum said it intends to defend vigorously; the filing did not state a clear loss estimate.
- Key risks include clinical and regulatory failure or delay, pociredir safety concerns, reliance on third-party manufacturers and trial contractors, limited collaboration revenue, need for additional capital and potential dilution, competition, and intellectual-property risks. Management stated disclosure controls were effective at the reasonable-assurance level and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether REACH remains on schedule and whether Q4 2024 topline timing or trial results change.
- Progress and safety findings in the resumed pociredir cohorts, including any renewed FDA restrictions and effects of revised eligibility criteria.
- Cash burn, investment returns and assumptions underlying the stated runway into 2026; potential need, timing and terms of additional financing.
- Developments in the securities class action, including any change in estimated exposure or legal costs.
- Future collaboration revenue and costs or milestones associated with the MyoKardia, GSK and CAMP4 arrangements, as well as dilution from outstanding equity awards and future financing.